← Leaderboards
Sarah Laun
Capsulomics, Llc
$2,691,319
Attributed
$2,691,319
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2023–24$2M$1.5M$1M$500K$0
'23
'24
Funding mix
By agency
NIH$2,691,319 · 2
By mechanism
R44$1,806,319 · 1
R42$885,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Capsulomics, Llc
Same institution · by research overlap
- Daniel Gregory Lunz$650,759
- John M Abraham$365,920
Others in their field
Other Rising Stars on “Invention”
- Daofeng Li · Salk Institute For Biological Studies$9,887,266
- Michael Hogarth · University Of California, San Diego$5,162,770
- Brian Smith · Case Western Reserve University$4,702,298
- Lee Cronin · University Of Glasgow$3,117,968
- Jorge H Jaramillo · Allen Institute$3,102,187
- Jayaram Chandrashekar · Allen Institute$3,102,187
Research focus
InventionMethylationFutureInnovationMarketingAlgorithmsEsophagusFundingGenesCostLaboratoriesMalignant NeoplasmsBiological MarkersBiomarker PanelEarly DiagnosisEpigenetic MarkerClinical ResearchFeedbackDiagnosisCohortCommercializationCase/Control StudiesDna MethylationPathway Interactions
Grant awards (3)
An accurate, affordable, and transferable assay for minimally invasive detection of esophageal squamous cell carcinoma (ESCC) in Africa and the United States$885,000
R42 · FY2024 · CA · contact PI
Validation and Early Commercialization of the ENVISAGE Assay, a Prognostic Test for Barrett's Esophagus$832,997
R44 · FY2024 · DK · contact PI
Validation and Early Commercialization of the ENVISAGE Assay, a Prognostic Test for Barrett's Esophagus$973,322
R44 · FY2023 · DK · contact PI